2,3,4,6-四特戊酰基-alpha-D-溴代吡喃葡萄糖可用于制备卡格列净。卡格列净(Canagliflozin)是第一个被FDA批准的SGLT2抑制剂药物,通过将葡萄糖分解后通过肾脏排出体外的方式降低血糖,用于治疗成人2型糖尿病,具有广阔的前景。
制备方法以ALPHA-D-葡萄糖为原料,经与特戊酰氯反应保护所有羟基后,再与溴化锌、三甲基溴硅烷在-10℃反应生成中间体。在此工艺中加入少量氯化亚砜,使特戊酰氯用量降低一半,收率无影响,两步收率都在82%以上,总收率大于67%。
中文名称 | 英文名称 | CAS号 | 化学式 | 分子量 |
---|---|---|---|---|
—— | 1,2,3,4,6-penta-O-pivaloyl-D-glucopyranose | 114179-84-9 | C31H52O11 | 600.747 |
—— | penta-O-pivaloyl-α-D-glucopyranoside | 1213234-53-7 | C31H52O11 | 600.747 |
(2S,3R,4S,5R,6R)-6-((新戊酰氧基)甲基)四氢-2H-吡喃-2,3,4,5-四 | 1,2,3,4,6-penta-O-pivaloyl-β-D-glucopyranose | 81058-26-6 | C31H52O11 | 600.747 |
中文名称 | 英文名称 | CAS号 | 化学式 | 分子量 |
---|---|---|---|---|
—— | 2,3,4,6-tetra-O-pivaloyl-D-glucopyranose | 148968-87-0 | C26H44O10 | 516.629 |
—— | 2,2-Dimethyl-propionic acid (2R,3R,4S,5R,6R)-3,5-bis-(2,2-dimethyl-propionyloxy)-2-(2,2-dimethyl-propionyloxymethyl)-6-((S)-3-hydroxy-1-methyl-propoxy)-tetrahydro-pyran-4-yl ester | 184648-42-8 | C30H52O11 | 588.736 |
—— | (1S,3R,4R,5S,6R)-3-((pivaloyloxy)methyl)-2,7-dioxabicyclo[4.1.0]heptane-4,5-diyl bis(2,2-dimethylpropanoate) | 163982-16-9 | C21H34O8 | 414.496 |
—— | methyl O-2,3,4,6-tetra-O-pivaloyl-β-D-glucopyranosyl-(1->3)-β-D-galactopyranoside | —— | C33H56O15 | 692.799 |
—— | methyl O-2,3,4,6-tetra-O-pivaloyl-β-D-glucopyranosyl-(1->2)-β-D-galactopyranoside | 1221265-13-9 | C33H56O15 | 692.799 |
—— | (S)-3-[(2R,3R,4S,5R,6R)-3,4,5-Tris-(2,2-dimethyl-propionyloxy)-6-(2,2-dimethyl-propionyloxymethyl)-tetrahydro-pyran-2-yloxy]-butyric acid | 184648-41-7 | C30H50O12 | 602.72 |